🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Going for your Sunday coffee run? Park a few steps away and stay out of that drive-through lane! AASLD EASLnews European Liver Patients' Association American Diabetes Association Obesity Matters Lilly Obesity International Novo Nordisk Madrigal Pharmaceuticals Shira zelber sagi Jonathan G. Stine, MD MSc, FACP Meena Bansal Sonal Kumar, MD MPH

We’re excited to share a valuable new resource for your patients with MASLD/MASH! Our latest blog & video, "Finding Strength and Support: Living with MASLD and MASH", is with Gina Villiotti Madison (Gina Villiotti-Madison), and offers real-world insights and practical strategies for

Living with Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) or its more severe form, Metabolic dysfunction-Associated Steatohepatitis (MASH), can feel overwhelming. During our recent Primary Care MASLD and MASH Summit, a conversation between Jeff McIntyre from

Thank you Scott Isaacs for highlighting our paper on cT1 prediction of histology response in MASH Perspectum . Arizona Liver Health FattyLiverAlliance Gene Im VCU Stravitz-Sanyal Institute for Liver Disease Mazen Noureddin, MD, MHSc

A newly published Nature Reviews Disease Primers article provides a comprehensive review of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). This condition affects over one-third of adults worldwide and is strongly linked to obesity, insulin resistance, and type

Check out this outstanding review of #MASLD for Nature Reviews Disease Primers. I am impressed with the 357 references! Dive into the latest insights and research priorities. Daniel Huang Vincent Wong Mary Rinella Jeffrey V. Lazarus boursier jerome Rohit Loomba Nature Reviews Disease Primers

Here is our final entry in our 10 part series for patients. Thank you Dr. Naim Alkhouri, MD, FAASLD for sharing your expertise and knowledge in this discussion. Advancements in MASH diagnosis and treatment are making it easier for healthcare providers to detect and manage the

Are you screening for MASLD? Nearly 40% of the global population has liver fat, and MASLD/MASH is now a leading cause of liver-related complications, cirrhosis, and liver cancer—yet most cases go undiagnosed. Key clinical insights from Dr. Supriya Joshi, MD's presentation at the

One of the best reviews out there on GLP1RAs for MASLD. I'm biased of course, lol. Mazen Noureddin, MD, MHSc Sonal Kumar, MD MPH Novo Nordisk Eli Lilly and Company Boehringer Ingelheim Arizona Liver Health FattyLiverAlliance Fatty Liver Foundation American Gastroenterological Association (AGA) tandfonline.com/doi/full/10.10…

News: Daily physical activity, even at low intensities, linked to lower cancer risk nih.gov/news-events/ne…

We’re excited to introduce the clinical trials education series on The Wellness League—our online platform designed for people living with steatotic liver disease and its associated chronic conditions. Deciding whether to participate in a clinical trial can feel overwhelming.

5 Reasons to Attend My Track Hub Presentation at EASL Congress 2025: Join me on May 8, 2025 from 16:15–16:45 at the Track Hub to explore how digital engagement is reshaping liver health. Here’s why you should be there: 1. See how smart wearables and CGMs provide real-time

Congratulations Professor Jeffrey V. Lazarus! Sherri and I (Michael Betel) are proud to be here at #AACE2025 with you and Julie and your parents to celebrate the incredible achievement of receiving the Eugene T. Davidson, MD, Public Service Award. This is a well-deserved recognition for your

At #AACE2025, Professor Jeffrey V. Lazarus delivered a comprehensive overview of the evolving landscape of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD and MASH), emphasizing why this matters now more than ever for endocrinologists and the broader medical community.

Dr. Kenneth Cusi one of the world’s foremost endocrinologists in metabolic liver disease, delivered a powerful reminder: endocrinologists are on the front lines of MASLD (formerly NAFLD) and MASH care—whether they realize it or not. Key Takeaways: •Type 2 diabetes & obesity are

At American Association of Clinical Endocrinology (AACE) #aace2025 conference, Dr. Scott Isaacs, FACP, FACE delivered a powerful call-to-action for Endocrinologists to take ownership of diagnosing and managing Metabolic dysfunction-Associated Steatotic Liver Disease

Today on Clinical Trials Day, we’re celebrating the incredible impact of clinical research professionals like you. Your dedication is what drives medical progress forward — from the earliest stages of discovery to tomorrow’s breakthrough treatments. Every protocol you design,